AstraZeneca's durvalumab combined with chemotherapy for treating resectable gastric and/or gastroesophageal junction cancer.

Patentradars sammanfattning

This PCT application (WO 2025/062351 A1) by AstraZeneca AB discloses methods and compositions for treating patients with resectable gastric cancer (GC) and/or gastroesophageal junction cancer (GEJC) using the anti-PD-L1 antibody durvalumab in combination with chemotherapy. The invention targets the perioperative or neoadjuvant/adjuvant treatment setting where surgical resection is intended. The claims fall under therapeutic antibody use (A61K 39/395), oncology treatment (A61P 35/00), and antibody structure against cell surface receptors (C07K 16/28), reflecting both the immunological and clinical dimensions of the invention.

AI-genererad och redaktionellt processad.